Halozyme Therapeutics, Inc. (HALO) Tops Q3 EPS by 9c, Sales Beat Expectations
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $107.10 -1.12%
EPS Growth %: +30.2%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
SUNB, CULP, KFY, More
EPS Growth %: +30.2%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q3 EPS of $0.05, $0.09 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $22.9 million versus the consensus estimate of $19.25 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
- Oddity Tech Ltd. (ODD) Tops Q2 EPS by 1c
- H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
